CureScience logo

CureScience

4 Followers

About

A San Diego based 501(c)(3) organization dedicated to developing curative therapies through a pre-emptive and personalized approach based on a) early diagnosis; b) immunology; and c) regenerative medicine. CureScienceTM is focused on accelerating the translation through in-house research, establishing ThinkTanks and a patient-centric ecosystem. The goal is to implement paradigm-shifting ways of “fast-forwarding” c...

No jobs yet!

Funding announcement

CureScience announces patient centric support through Cureosyti program

Grant Opportunities $2,500-$25,000 CureScienceTM Institute is engaged in patient-centric research and development towards the discovery, development and production of novel medicines in a variety of therapeutic areas including but not limited to oncology, immunology and regenerative medicine. CureScienceTM, a 501(c)(3) nonprofit organization, focuses on research and development, patient development and the long term goal of providing quality health care products. CureScienceTM establishes and funds its own programs and also provides grants for other 501(c)(3) organizations engaged in patient care. CureScienceTM is seeking innovative patient engagement proposals that address patient care, patient support and/or patient education. Funding Amounts: Grants will be awarded in the amounts of $2,500-$25,000. The maximum funding amount for each patient engagement grant is up to $25,000. Grant information and applications available at [https://www.curescience.org/grants]

Team announcement

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

CureScienceTM Institute, a San Diego-based 501(c)(3) non-profit organization dedicated to accelerating novel curative therapies, announced today that Dr. Boris Reznik, has joined the organization's Advisory Board. Dr. Reznik is a veteran of multiple startups and has a strong track record of building companies across a diverse set of technologies-based industries with biomedical sciences being one of his primary focuses. Boris Reznik is the Chairman of Venvalo Group, venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems – a unique perspective in the drug and device development world. As the Chairman of Biorasi, a global CRO, he led development of novel therapeutics, from filing IND to getting approved NDA, for companies ranging from startups to Big Pharma. "I am delighted to welcome Dr. Reznik to our Advisory Board," said Dr. Shashaanka Ashili, CEO of CureScienceTM Institute. "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr. Reznik's counsel as we work towards developing personalized therapeutic approaches." "CureScienceTM is a nonprofit institute with a strong team of professionals and an agile approach to novel therapeutics development," said Dr. Reznik. "I am impressed by CureScienceTM 's unconventional methodologies to improving patients' lives. With the rapidly changing life sciences industry, partnerships and collaborations are key to advancing science and I look forward to working with the CureScienceTM team on this front." "Dr. Reznik's experience in novel therapeutics development will be valuable to the researchers at CureScienceTM as we navigate the complex world of translating innovations and discoveries into clinical applications," said Dr. Tom Ichim, Director, Clinical Sciences at CureScienceTM. The Institute is committed to developing a preemptive and personalized approaches based on the early diagnosis, immunology, and regenerative medicine. To this end, CureScienceTM is focused on accelerating research and development programs internally and through the establishment of strategic partnerships with academic and industry partners. More information on CureScience at [www.CureScience.org] More information on Boris Reznik at [www.venvalo.com] [https://www.prnewswire.com/news-releases/curescience-institute-names-dr-boris-reznik-as-advisory-board-member-301233633.html]

Product announcement

Advancing healthcare through co-creation

Advancing healthcare through co-creation

With a philosophy of “cocreate, not compete,” the Sorrento Valley-based nonprofit CureScience Institute is working to advance health care treatments that are more personalized to the patient. CureScience started with a focus on brain cancer research. It is now supporting work to develop curative therapies for cancer, immune and neurological disorders, in addition to using regenerative medicine to cure many different types of human health issues. “We expanded the mission and vision,” said Shashaanka Ashili, CureScience’s CEO. “Now we are looking to develop the framework where we can look into multiple disorders, multiple diseases.” He said a key component of that goal is developing a more holistic approach to putting vast quantities of data to use. “Google has some data, Apple has some data, Facebook has some data, some others have some data,” Ashili said. “Then you have the whole health care system which also has its own silos. Is it time to ask, can we put all these things together? And if so, how?” He added, “The resounding answer to that is yes. That time was yesterday.” The scope of CureScience’s work also includes COVID-19, which has killed more than 1 million people worldwide with vaccines still in development. “By March it struck us all that nobody’s escaping COVID,” Ashili said. “It’s going to disrupt every business and it’s going to change everything.” CureScience’s active mesenchymal stem cell research program could have implications for COVID-19 treatments, and could also yield insights into treating Alzheimer’s disease, which still has no effective treatments that can reverse symptoms. Other unmet patient needs that CureScience would like to address include noninvasive ways to diagnose and monitor the treatment of brain tumors. The institute is also supporting immunotherapy, in which the body’s immune system can be better deployed to fight cancer. The institute is also working in many other areas to bring about more “patient-driven” ways to improve health care. “In the next two years, we should have a framework where we can say this is what patient-driven health care looks like,” Ashili said, adding that the framework also has to showcase the value to patients. “Once we have that, the sky is the limit,” he continued. To help advance its work, CureScience is holding a virtual donor gala on Nov. 21. The event will feature an auction and guest speakers. The institute is located at 10225 Barnes Canyon Road. For more information, visit curescience.org [https://www.delmartimes.net/news/health-science/story/2020-10-27/curescience-ceo-wants-to-cocreate-not-compete-to-advance-health-care]

Team announcement

Dr. Marincola joins CureScience Advisory Board

Dr. Marincola joins CureScience Advisory Board

CureScience™ Institute, a San Diego-based 501(c)(3) non-profit institute dedicated to accelerating novel curative therapies, is pleased to announce that Francesco Marincola, M.D. will join the Advisory Board. "We're honored to have Dr. Francesco Marincola on the advisory board," said Dr. Shashaanka Ashili, CEO of CureScience™ Institute. "As a world leader in tumor immunology, tumor microenvironment, and translational research, Dr. Marincola's experience will be invaluable in advancing the CureScience™ mission and positively impacting patients' lives through development of personalized therapeutic approaches," said Dr. Feng Lin, Lead Immunology Scientist at the Institute. Dr. Marincola is currently Chief Scientific Officer and President at Refuge Biotech where he leads the development of a cell therapy platform. Prior to joining Refuge Biotech, he served as a distinguished research fellow and strategist for immune oncology discovery at AbbVie. In addition, Dr. Marincola developed and led a genetic research institute at Sidra Medical and Research Center in Qatar; and served as Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the NIH in Bethesda. Dr. Marincola received his M.D. from the University of Milan, and completed his surgery training at Stanford University. He has published more than 600 original articles, reviews, editorials, and books. CureScience™ Institute is committed to developing a preemptive and personalized approach to medicine based on early diagnosis, immunology, and regenerative medicine. To this end, CureScience™ is focused on accelerating research and development programs internally and externally through the establishment of strategic partnerships with academic and industry partners. The addition of Dr. Marincola will particularly help drive the immunology program at CureScience™. "CureScience™ has a strong foundation in place with a talented and multidisciplinary team of scientists," said Dr. Marincola. "I'm excited to join as a member of the advisory board working with researchers to advance the clinical development of novel approaches." For more information at [www.CureScience.org] Media contact: Lawrence D. Jones, Ph.D. CureScience™ Institute (858) 800 CURE (2873) [https://www.prnewswire.com/news-releases/curescience-institute-announces-dr-franco-marincola-as-new-advisory-board-member-301123939.html]

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.